肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理

2019-12-13 国外肿瘤科相关专家小组（统称） Clin Oncol (R Coll Radiol). 2019 Dec 13.

乐伐替尼甲状腺癌不良事件

乐伐替尼是一种口服多激酶抑制剂，经批准用于治疗侵袭性、局部进展或转移、放射碘不敏感的分化型甲状腺癌。本文主要针对乐伐替尼治疗甲状腺癌期间不良事件的管理提供共识指导。

中文标题：

2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理

英文标题：

Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2019-12-13

简要介绍：

乐伐替尼是一种口服多激酶抑制剂，经批准用于治疗侵袭性、局部进展或转移、放射碘不敏感的分化型甲状腺癌。本文主要针对乐伐替尼治疗甲状腺癌期间不良事件的管理提供共识指导。

 

拓展指南：与甲状腺癌相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理)] GetToolGuiderByIdResponse(projectId=1, id=1abc31c0018a2112, title=2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理, enTitle=Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer., guiderFrom=Clin Oncol (R Coll Radiol). 2019 Dec 13., authorId=null, author=, summary=乐伐替尼是一种口服多激酶抑制剂，经批准用于治疗侵袭性、局部进展或转移、放射碘不敏感的分化型甲状腺癌。本文主要针对乐伐替尼治疗甲状腺癌期间不良事件的管理提供共识指导。 , cover=, journalId=null, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Fri Dec 13 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>乐伐替尼是一种口服多激酶抑制剂，经批准用于治疗侵袭性、局部进展或转移、放射碘不敏感的分化型甲状腺癌。本文主要针对乐伐替尼治疗甲状腺癌期间不良事件的管理提供共识指导。</P> <P> </P>拓展指南：<strong>与<font color=red>甲状腺癌</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=8f5dc1c001823621" title="分化型甲状腺癌术后 131 I治疗前评估专家共识" target=_blank>分化型甲状腺癌术后 131 I治疗前评估专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=d13ad1c001e9935a" title="2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访" target=_blank>2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=96b171c001e976ed" title="NCCN临床实践指南：甲状腺癌（2019.V2）" target=_blank>NCCN临床实践指南：甲状腺癌（2019.V2）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=53e351c001e683f2" title="碘难治性分化型甲状腺癌的诊治管理共识（2019年版）" target=_blank>碘难治性分化型甲状腺癌的诊治管理共识（2019年版）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=2c1341c001e3507e" title="2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）" target=_blank>2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E7%94%B2%E7%8A%B6%E8%85%BA%E7%99%8C" target=_blank>有关甲状腺癌更多指南</a></ul>, tagList=[TagDto(tagId=38952, tagName=乐伐替尼), TagDto(tagId=865, tagName=甲状腺癌), TagDto(tagId=2866, tagName=不良事件)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9542, appHits=160, showAppHits=1, pcHits=7402, showPcHits=2805, likes=88, shares=2, comments=3, approvalStatus=1, publishedTime=Tue Dec 24 21:23:43 CST 2019, publishedTimeString=2019-12-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Dec 24 21:23:43 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 21:40:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理)])
2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1067855, encodeId=5522106e85502, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:00 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944871, encodeId=2efc9448e163, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Tue Mar 02 18:36:53 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897981, encodeId=b01b89e9813e, content=<a href='/topic/show?id=9c8b23365fb' target=_blank style='color:#2F92EE;'>#乐伐替尼#</a>，也就是<a href='/topic/show?id=341f25314f1' target=_blank style='color:#2F92EE;'>#仑伐替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23365, encryptionId=9c8b23365fb, topicName=乐伐替尼), TopicDto(id=25314, encryptionId=341f25314f1, topicName=仑伐替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:31:12 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2021-11-07 1471d48dm72暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1067855, encodeId=5522106e85502, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:00 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944871, encodeId=2efc9448e163, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Tue Mar 02 18:36:53 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897981, encodeId=b01b89e9813e, content=<a href='/topic/show?id=9c8b23365fb' target=_blank style='color:#2F92EE;'>#乐伐替尼#</a>，也就是<a href='/topic/show?id=341f25314f1' target=_blank style='color:#2F92EE;'>#仑伐替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23365, encryptionId=9c8b23365fb, topicName=乐伐替尼), TopicDto(id=25314, encryptionId=341f25314f1, topicName=仑伐替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:31:12 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2021-03-02 1471d48dm72暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1067855, encodeId=5522106e85502, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:00 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944871, encodeId=2efc9448e163, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Tue Mar 02 18:36:53 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897981, encodeId=b01b89e9813e, content=<a href='/topic/show?id=9c8b23365fb' target=_blank style='color:#2F92EE;'>#乐伐替尼#</a>，也就是<a href='/topic/show?id=341f25314f1' target=_blank style='color:#2F92EE;'>#仑伐替尼#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23365, encryptionId=9c8b23365fb, topicName=乐伐替尼), TopicDto(id=25314, encryptionId=341f25314f1, topicName=仑伐替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:31:12 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2020-11-09 lovetcm

    #乐伐替尼#，也就是#仑伐替尼#

    0